TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20450672

Group type: EXPERIMENTAL
Intervention: Aspherical IOL
Number of subjects: 436

Group type: COMPARATOR
Intervention: Spherical IOL
Number of subjects: 436
Study: 18304620

Group type: EXPERIMENTAL
Intervention: Yttrium‐90‐labeled human milk fat globule 1 murine monoclonal antibody (90Y‐muHMFG1)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Affinity chromatography of serum samples with high CA 125 values
Number of subjects: 447
Study: 15830972

Group type: EXPERIMENTAL
Intervention: Percutaneous cervical nucleoplasty using coblation technology
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment with medical and physical therapy
Number of subjects: 50
Study: 14559420

Group type: EXPERIMENTAL
Intervention: Cold environment (5 degrees C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Warm environment (35 degrees C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No control over temperature
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thermoneutral environment (20 degrees C)
Number of subjects: 50
Study: 10484900

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (Group A)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 192
Study: 9085534

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy (OA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustable oral appliances (OA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 0
Study: 1751444

Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol sodium daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unrestricted sodium intake
Number of subjects: 42
Study: 7128187

Group type: EXPERIMENTAL
Intervention: 1.5 g glucosamine sulphate daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.2 g ibuprofen daily
Number of subjects: 40
Study: 31557755

Group type: EXPERIMENTAL
Intervention: Self-reported acne vulgaris (AV)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Clinical examination for acne vulgaris (AV)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Gender (female vs male)
Number of subjects: 714

Group type: COMPARATOR
Intervention: BMI categories (overweight/obese vs normal weight)
Number of subjects: 714
Study: 31017456

Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TrP‐DN) of sternocleidomastoid
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 30567694

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention with technical measurements (IMUs, sEMG, heart rate monitoring, video recordings)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 27707497

Group type: EXPERIMENTAL
Intervention: Clear-lens extraction
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 419

Group type: COMPARATOR
Intervention: Clear-lens extraction vs Standard care
Number of subjects: 419
Study: 25799845

Group type: EXPERIMENTAL
Intervention: Smoking group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Tobacco-abstinent group
Number of subjects: 85
Study: 22425689

Group type: EXPERIMENTAL
Intervention: Microencapsulated Lactobacillus reuteri NCIMB 30242 in yogurt, 5 × 10(10) CFU, twice/day for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Microencapsulated Lactobacillus reuteri NCIMB 30242 in yogurt
Number of subjects: 120
Study: 20717800

Group type: EXPERIMENTAL
Intervention: Visuomotor adaptation with a misaligned cursor rotated 30 degrees clockwise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuomotor adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprioceptive recalibration
Number of subjects: 0
Study: 18853556

Group type: EXPERIMENTAL
Intervention: Kanizsa square-like rivalry displays with vertical illusory contours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated stimulus conditions (switching half-images, relocating pacmen, placing pacmen diagonally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 135 degree-grating disc in rivalry with a 135 degree-grating pacman on a 45 degree-grating background
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alignment of images in the two eyes
Number of subjects: 0
Study: 15807452

Group type: EXPERIMENTAL
Intervention: Colloid bismuth subcitrate (CBS) 240 mg twice a day + amoxicillin 2 g/day and furozolidon 400 mg/day (subgroup 1a, n = 10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Colloid bismuth subcitrate (CBS) monotherapy 240 mg twice a day (subgroup 1b, n = 20)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day (group 2, n = 15)
Number of subjects: 45
Study: 12058489

Group type: EXPERIMENTAL
Intervention: Vitrectomy without the use of microscissors
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vitrectomy with the use of microscissors
Number of subjects: 24
Study: 10703658

Group type: EXPERIMENTAL
Intervention: Guidor Matrix Barrier (membrane placement)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional flap surgery only
Number of subjects: 16
Study: 9505333

Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement with 24% EDTA solution as irrigation agent
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional application of irrigation fluid
Number of subjects: 24
Study: 8475962

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 micrograms/ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetaminophen (100 micrograms/ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indomethacin (10 micrograms/ml)
Number of subjects: 6
Study: 3092657

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms twice daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms twice daily (in smokers)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily (in smokers)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (in smokers)
Number of subjects: 128
Study: 31450067

Group type: COMPARATOR
Intervention: Regular rhythm track
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderately syncopated rhythm track
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly syncopated rhythm track
Number of subjects: 0
Study: 29095191

Group type: EXPERIMENTAL
Intervention: Ultrasonic Doppler monitoring of popliteal artery blood flow; tourniquet pressure set until maximum systolic velocity reduced to 0.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard tourniquet pressure determined by doctor's request, not exceeding 80 KPa.
Number of subjects: 96
Study: 28477505

Group type: EXPERIMENTAL
Intervention: BRAVE‐ONLINE (NET)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 42
Study: 26233499

Group type: EXPERIMENTAL
Intervention: 80 mg intraarticular triamcinolone acetonide
Number of subjects: 97

Group type: COMPARATOR
Intervention: 40 mg intraarticular triamcinolone acetonide
Number of subjects: 97
Study: 24264552

Group type: EXPERIMENTAL
Intervention: Pregabaline 150 mg 1 hr before operation and 75 mg 12 hr after operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo empty capsule
Number of subjects: 60
Study: 21393587

Group type: EXPERIMENTAL
Intervention: Implementation strategy (5 meetings based on the Breakthrough Series model)
Number of subjects: 5515

Group type: COMPARATOR
Intervention: Control (no implementation strategy)
Number of subjects: 5515
Study: 18942248

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microg/kg (Group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine 1.5 mg/kg (Group P)
Number of subjects: 60
Study: 16798309

Group type: EXPERIMENTAL
Intervention: BioGlue (surgical treatment and BioGlue)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (surgical treatment only)
Number of subjects: 52
Study: 12678218

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0
Study: 11077224

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) therapy
Number of subjects: 38
Study: 9372290

Group type: EXPERIMENTAL
Intervention: Constant acceleration, constant deceleration, and constant velocity targets with motion times from 0.5 to 2.0 s
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Threshold-distance model
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Threshold-tau model
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Dual-strategy model (reactive and predictive strategies)
Number of subjects: 2614
Study: 1534001

Group type: EXPERIMENTAL
Intervention: recombinant human IFN gamma (rhIFN gamma)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 30506961

Group type: EXPERIMENTAL
Intervention: ProMax 3D Max with low mode artefact reduction (AR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ProMax 3D Max without artefact reduction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pax Flex 3D
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dentri S
Number of subjects: 40
Study: 28072660

Group type: EXPERIMENTAL
Intervention: Active HF-rTMS (2 sessions per day)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Active HF-rTMS (1 session per day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham stimulation (1 session per day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham stimulation (2 sessions per day)
Number of subjects: 98
Study: 26579629

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy for anxiety
Number of subjects: 73
Study: 23825078

Group type: EXPERIMENTAL
Intervention: Exercise-induced muscle damage (EIMD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-muscle-damaging flat run (CON)
Number of subjects: 10
Study: 22827782

Group type: EXPERIMENTAL
Intervention: Low dose zinc supplementation (50 mg elemental Zn sulfate daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose zinc supplementation
Number of subjects: 60
Study: 19851126

Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 252
Study: 17300591

Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitors (e.g., vildagliptin, sitagliptin)
Number of subjects: 0
Study: 16392769

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid supplements (1,800 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Diet therapy (control group)
Number of subjects: 84
Study: 11979054

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg cortisol intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 20
Study: 11477843

Group type: EXPERIMENTAL
Intervention: Shuanghuanglian Powder (SHLP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional therapy alone (Control)
Number of subjects: 62
Study: 8584966

Group type: EXPERIMENTAL
Intervention: Activated back spoiler mechanism
Number of subjects: 10

Group type: COMPARATOR
Intervention: Blocked back spoiler mechanism
Number of subjects: 10
Study: 2547408

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 799987

Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 30762735

Group type: EXPERIMENTAL
Intervention: TIVA/PCIA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TIVA/PCEA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TEA-IVA/PCIA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TEA-IVA/PCEA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCEA groups
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCIA groups
Number of subjects: 100
Study: 29548729

Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 60 sessions
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 90 sessions
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 60 sessions
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 90 sessions
Number of subjects: 565

Group type: COMPARATOR
Intervention: Sham-control group (Group A)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: UGIB rates in Groups B and C
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: UGIB rates in Groups D and E
Number of subjects: 565
Study: 26912230

Group type: EXPERIMENTAL
Intervention: Pre-calling participants before the 8-month follow-up questionnaire (Study 1)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Research team photograph sent with the 12-month questionnaire (Study 2)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Action-oriented email reminder ('ACTION REQUIRED') for the 12-month questionnaire (Study 3)
Number of subjects: 609
Study: 25280524

Group type: EXPERIMENTAL
Intervention: Paced diaphragmatic breathing (DB) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition focusing on environmental awareness
Number of subjects: 60
Study: 23034059

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention promoting electronic prompts for stroke secondary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 19244039

Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer
Number of subjects: 176
Study: 17325899

Group type: EXPERIMENTAL
Intervention: Pixantrone 80 mg/m2, methylprednisolone 500 mg, cisplatin 25 mg/m2, cytarabine 2000 mg/m2
Number of subjects: 19
Study: 15049795

Group type: EXPERIMENTAL
Intervention: Sirolimus (1, 3, 9, or 15 mg/m(2))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11875681

Group type: EXPERIMENTAL
Intervention: 0.25% nitroglycerin topically (administered in two daily applications for two weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional treatment (placebo)
Number of subjects: 43
Study: 9667801

Group type: EXPERIMENTAL
Intervention: 3 million units (MU) three times per week for 6 months
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 3 million units (MU) three times per week for 12 months
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 6 million units (MU) three times per week for 6 months
Number of subjects: 255
Study: 7774300

Group type: EXPERIMENTAL
Intervention: Tetracycline pleurodesis (TCP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Tube thoracostomy alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 78
Study: 2925704

Group type: EXPERIMENTAL
Intervention: Early stabilization of femoral fractures
Number of subjects: 178

Group type: COMPARATOR
Intervention: Delayed stabilization of femoral fractures
Number of subjects: 178
Study: 31881954

Group type: EXPERIMENTAL
Intervention: Psychiatric Advance Directives (PAD)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 400
Study: 28629540

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OXT) at a dose of 24 international units, administered 45-70 minutes prior to testing
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 116
Study: 25281353

Group type: EXPERIMENTAL
Intervention: Mendelian randomisation analysis using SNPs related to 25(OH)D synthesis and metabolism.
Number of subjects: 104488

Group type: COMPARATOR
Intervention: Meta-analysis of observational studies (8492 cases, 89,698 non-cases).
Number of subjects: 104488

Group type: EXPERIMENTAL
Intervention: Mendelian randomisation analysis for glycaemic traits.
Number of subjects: 104488
Study: 23318811

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Proseal (LMAP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway Supreme (LMAS)
Number of subjects: 120
Study: 21084392

Group type: EXPERIMENTAL
Intervention: Intraarterial ghrelin infusion (4.2 ng × kg(‐1) × min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intraarterial placebo infusion
Number of subjects: 8
Study: 19335977

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil for 48 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil in combination with lamivudine for the first 12 weeks and adefovir dipivoxil only for the following 36 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil in combination with lamivudine for 48 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Entecavir for 48 weeks
Number of subjects: 120
Study: 17602082

Group type: EXPERIMENTAL
Intervention: Single high-dose chemotherapy (CE): one cycle of cisplatin 100 mg/m2, etoposide 375 mg/m2, and ifosfamide 6 g/m2 plus three cycles of high-dose carboplatin 1,500 mg/m2 and etoposide 1,500 mg/m2
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sequential high-dose chemotherapy (CEC): three cycles of VIP plus one cycle of high-dose carboplatin 2,200 mg/m2, etoposide 1,800 mg/m2, and cyclophosphamide 6,400 mg/m2
Number of subjects: 216
Study: 15910203

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.25 mg/kg body weight
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg body weight
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12111764

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg PO and diphenhydramine 25 mg IV
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 10533975

Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 64
Study: 7473375

Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 551

Group type: COMPARATOR
Intervention: Gd‐DOTA
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA‐BMA
Number of subjects: 551
Study: 2037709

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6267142

Group type: EXPERIMENTAL
Intervention: CMV-infected monocytes
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Monocyte depletion
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lymphocyte responses to concanavalin A (con A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Uninfected monocytes
Number of subjects: 2
Study: 31163689

Group type: EXPERIMENTAL
Intervention: Herbal mixture (700 mg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Herbal mixture (700 mg daily) along with Clomiphene Citrate (CC) (50-150 mg for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) (50-150 mg for 3 months)
Number of subjects: 60
Study: 28586828

Group type: EXPERIMENTAL
Intervention: Enhanced milieu teaching with phonological emphasis (EMT+PE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Business-as-usual (BAU)
Number of subjects: 19
Study: 25961147

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Social Behavior and Network Therapy (SBNT)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Therapist WAI
Number of subjects: 173
Study: 23828457

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 44
Study: 22011274

Group type: EXPERIMENTAL
Intervention: Gastro-gastric suture (GGS) for band fixation (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No gastro-gastric suture (Group 2)
Number of subjects: 80
Study: 19267775

Group type: EXPERIMENTAL
Intervention: Torasemide-PR (10 mg daily for 4 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Torasemide-IR (10 mg daily for 4 days)
Number of subjects: 16
Study: 17077394

Group type: EXPERIMENTAL
Intervention: Telephone outreach intervention
Number of subjects: 456

Group type: COMPARATOR
Intervention: Direct mail approach (Control)
Number of subjects: 456
Study: 14984448

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 78
Study: 11297201

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 87

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 87
Study: 9469236

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0
Study: 7715469

Group type: EXPERIMENTAL
Intervention: Climen (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prempak-C (0.625 mg conjugated equine estrogens and 0.15 mg norgestrel)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Climen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prempak-C
Number of subjects: 38
Study: 3145752

Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: 60 mg terfenadine twice daily
Number of subjects: 191
Study: 29429612

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg once daily (or 5 mg once daily for patients with creatinine clearance 40 to 60 mL/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study: 28651417

Group type: EXPERIMENTAL
Intervention: Specially-assigned person rehabilitation group (SAPR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propaganda education rehabilitation group (PER)
Number of subjects: 44